Back to today’s briefing

Story perspectives

AstraZeneca Acquires Global Rights to C-CAR031 Therapy

1/20/2026

29 4

Summary

Story summary

AstraZeneca has secured full global rights to the GPC3-targeting CAR-T therapy C-CAR031 by acquiring the remaining rights in China for up to $630 million.
The move follows a 2023 partnership with AbelZeta Pharma to develop the therapy for hepatocellular carcinoma (HCC).
C-CAR031 is designed to address challenges in treating solid tumors, and the deal signals a shift toward integrated global programs for solid tumor therapies.

1 of 1

Story summary

AstraZeneca has secured full global rights to the GPC3-targeting CAR-T therapy C-CAR031 by acquiring the remaining rights in China for up to $630 million.
The move follows a 2023 partnership with AbelZeta Pharma to develop the therapy for hepatocellular carcinoma (HCC).
C-CAR031 is designed to address challenges in treating solid tumors, and the deal signals a shift toward integrated global programs for solid tumor therapies.